Cargando…
Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial
BACKGROUND: Metformin is the first-line treatment for type 2 diabetes mellitus (T2DM), but many patients either cannot tolerate it or cannot achieve glycemic control with metformin alone, so treatment with other glucose-lowering agents in combination with metformin is frequently required. Remogliflo...
Autores principales: | Dharmalingam, Mala, Aravind, S. R., Thacker, Hemant, Paramesh, S., Mohan, Brij, Chawla, Manoj, Asirvatham, Arthur, Goyal, Ramesh, Shembalkar, Jayashri, Balamurugan, R., Kadam, Pradnya, Alva, Hansraj, Kodgule, Rahul, Tandon, Monika, Vaidyanathan, Sivakumar, Pendse, Amol, Gaikwad, Rajesh, Katare, Sagar, Suryawanshi, Sachin, Barkate, Hanmant |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7165159/ https://www.ncbi.nlm.nih.gov/pubmed/32162274 http://dx.doi.org/10.1007/s40265-020-01285-0 |
Ejemplares similares
-
Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin
por: Dobbins, Robert, et al.
Publicado: (2021) -
Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy
por: Mohan, Viswanathan, et al.
Publicado: (2020) -
Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects
por: Napolitano, Antonella, et al.
Publicado: (2013) -
Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes
por: Mudaliar, Sunder, et al.
Publicado: (2012) -
Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus
por: Hussey, Elizabeth K, et al.
Publicado: (2013)